ESTRELLA IMMUNOPHARMA, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.19 million for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-27.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2024-11-14
- ESTRELLA IMMUNOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-09-30 was $1.19M, a 1066.66% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-03-31 was $102.40K.
- ESTRELLA IMMUNOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2022-12-31 was $102.40K.
- ESTRELLA IMMUNOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2022-09-30 was $102.40K.
- ESTRELLA IMMUNOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.19M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2024-06-30 | $1.19M 10-K · filed 2024-09-27 | |||
| 2023-09-30 | $1.19M 10-Q · filed 2024-11-14 | |||
| 2023-03-31 | $102.40K 10-Q · filed 2024-05-15 | $204.80K derived: sum of 2 quarters · filed 2024-05-15 | $307.20K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | $102.40K 10-Q · filed 2024-05-15 | $204.80K derived: sum of 2 quarters · filed 2024-05-15 | ||
| 2022-09-30 | $102.40K 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |